Potential of anticytokine therapies in central nervous system ischaemia

Expert Opinion on Biological Therapy

Volumn 1, Issue 2, 2001, Pages 227-237

  Clark, Wayne M ^a   Lutsep, Helmi L ^b  

^a Oregon Stroke Center   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Central nervous system; Cytokines; IL 6; Interleukins; Stroke

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 6; NEUROPROTECTIVE AGENT; TUMOR NECROSIS FACTOR;

ANIMAL; BLOOD; BRAIN; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG EFFECT; HUMAN; INFLAMMATION; LEUKOCYTE; METABOLISM; REVIEW;

ANIMAL; BRAIN; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CYTOKINES; HUMAN; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-6; LEUKOCYTES; NEUROPROTECTIVE AGENTS; TUMOR NECROSIS FACTOR;

EID: 0035294675     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.2.227     Document Type: Article

References (79)

1. KOCHANEK PM, HALLENBECKJM: Potymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke (1992) 23:1267-1379.
2. DENVENISTE EN: Inflammatory cytoklnes within the central nervous system: sources, function, and mechanism of action. Am. J. . Pbysiol. (1992) 263:Cl-Cl6.
3. FEUERSTEIN GZ, WANG X, YUE TL, BARONE FC: Inflammatory cytokines and stroke: emerging new strategies for stroke therapeutics. In: Cercbrovascular Diseases: Nineteenth Princeton Stroke Conference. Moskowitz MA, Caplan LR (Eds.), Butterworth-Heinemann, Newton, MA (1995):75-91. Good review of topic.
4. MINAMI M, KURAISHI Y, YABUUCHI K, YAMAZAKI A, SATOH M: Induction of lnterleukin-lβ niRNA in rat brain after transient forebrain ischemia.J. Ncurocbem. (1991) 58:390-392.
5. FASSBENDER K, ROSSOL S, KAMMER T et al.: Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J. Neural. Sei. (1994) 122:135-139. Measures acute cytokine changes post-clinical stroke.
6. TARKOWSKI E, ROSENGREN L, BLOMSTRAND C et al.: Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke (1995) 26:1393-1398. Demonstrates the relationship between CSF IL-6 and final infarct size.
7. LUI T, YOUNG PR, MCDONNELL PC, WHITE RF, BARONE FC, FEUERRSTEIN GZ: Cytokine-induced neutrophil chemoattractant mRNA expressed in cerebral ischemia. Keuroscietices Lett. (1993) 164:125-128.
8. KIM JS, GAUTAM SC, CHOPP M et al: Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 after focal cerebral ischemia in the rat.J. Neuroimmunol. (1995) 56:127-134a.
9. KIM JS: Cytokines and adhesion molecules in stroke and related diseases.J. Neural. Sei. (1996) 137:69-78. Brief overview of area.
10. KOCHANEK PM, HALLENBECK JM: Potymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke (1992) 23:1367-1379.
11. CLARK WM, MADDEN KP, ROTHLEIN R, ZIVIN JA: Reduction of central nervous system ischémie injury by monoclonal antibody to intercellular adhesion molecule.J. Keurosurg. (1991) 75:623-627.
12. CLARK WM, MADDEN KP, ROTHLEIN R, ZIVIN JA: Reduction of central nervous system ischémie injury in rabbits using leukocyte adhesion antibody treatment. 5/rote(1991) 22:877-883.
13. SEI Y, VITKOVIC L, YOKOYAMA MM: Cytokines in the central nervous system: regulatory roles in neuronal function, cell death and repair. Neumlmmiinoinodiilation (1995) 2:121-133.
14. DINARELLO CA, GELFAND JA, WOLFF SM: Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA (1993) 269:1829-1835.
15. CHUNG IL, BENVEN1STE EN: Tumor necrosis factor production by astrocytes: Induction by lipo polys acharide,IFN-y, and IL-1β.J. Immunol. (1990) 144:2999-3007.
16. ALOISI F, CAR F, BORSELUNO G et al: Production of hemolymphopoietic cytokines (IL-6, IL-8, colonystimulating factors) by normal human astrocytes in response to EL-l and tumor necrosis factor-o. J. Immunol. (1992) 149:2358-2366.
17. SELMAJ K, FAROOQ M, NORTON WT, RAINE CS, BROSNAN CF: Proliferation of astrocytes in vitro in response to cytokines: a primary role for tumor necrosis factor.J. Immunol. (1990) 144:129-135.
18. FISHER C, SLOTMAN GJ, OPAL S: Interleukin-1 receptor antagonist reduces mortality in patients with sepsis syndrome. Presented at the fourth annual meeting of the American College of Chest Physicians. San Francisco, California, USA (1991).
19. MCCARTHY PL, ABHYANKAR S, NEBEN S et al.: Inhibition of interieukln-1 by interleukin-1 receptor antagonist prevents graft versus host disease. Blood (1991) 78:1915-1918.
20. OHLSSON K, BJORK P, BERGENFELDT M, HAGEMAN R, THOMPSON RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature(.1990) 348:550-552.
21. AIURA K, GELFAND JA, WAKABAYASHI G: Interleukin-1 receptor antagonist blocks staphylococcal Induced shock in rabbits. Cytokine(1991) 3:498.
22. GERSHENWALD JE, FONG YM, FAHEY TJ III et al.: Interleukin-1 receptor blockade attenuates the host inflammatory response. Proc. Nail. Acad. Sei. USA (1990) 87:4966-4970.
23. DI SANTO E, SIRONI M, POZZI P et ah. Interleukin-10 inhibits lipopolysaccharide-lnduced tumor necrosis factor and interleukin-1 production in the brain without affecting the activation of the hypothalamuspituitary-adrenal axis. Keuroimmimomodulatton (1995) 2:149-154.
24. BLACKWELL TS, CHRISTMAN JW: Sepsis and cytokines: current status. Br.J. Anaesth. (1996) 77:110-117. Good review of topic.
25. FISHER CJ, DHAINAUT JF, OPAL SM et al.: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial. JAMA (1994) 271:1836.
26. OPAL SM, FISHER CJ Jr, DHAINAUT JF et al., Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. CriJ. Cure Mod. (1997)25(7):1115-1124.
27. LEBSACK ME, PAUL CG, BLOEDOV7 DC et a!.: Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. (1991) 34:567.
28. THACKRAY S, WITTE K, CLARK A, CLELAND J: Clinical trials update: OPTIME. Eur. J. Heart Failure (2000) 2:209-212.
29. ROTHWELL NJ, HOPKINS SJ: Cytokines and the nervous system II: actions and mechanisms of action. Trends Kciirosci. (1995) 18:130-136. Good review.
30. ROTHWELL N: Functions and mechanism of IL-1 in the brain. Trends Pbannacol. Set. (1991) 12:430-435.
31. WANG XK, YUE T-L, BARONE FC, WHITE RF, GAGNON RC, FEUERSTEIN GZ: Concomitant cortical expression of TNFa and IL-1β m RNA following transient focal ischemia. Mol. Cbem. Netiropatbol (1994) 23:103-114.
32. YAMASAKI Y, MATSUURA N, SHOZUHARA H, ONODERA H, ITOYAMA Y, KOGLIRE K: Interleukin-1 as a pathogeneue mediator of ischémie brain damage in rats. Stroke (1995) 26:676-681.
33. RELTON JK, ROTHWELL NJ: Interleukin-1 receptor antagonist inhibits ischémie and excitotoxic neuronal damage in the rat Brain Res. Bull. (1992) 29:243-246 Initial report of IL-lra treatment effect.
34. GARCIA JH, LIU KF, RELTON JK: Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. Am. J. Palhol (1995) 147:1477-1486.
35. LODDICK SA, ROTHWELL NJ: Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischemia in the rat.J. Cercb. Blood FlowMetab. (1996) 16(5):932-940.
36. BETZ AL, YANG GY, AND DAV1DSON BL: Attenuation of stroke size in rats using an adenoviral vector to induce ovcrcxprcssion of interleukin-1 receptor antagonist in brain. J. Cercb. Blood flow Metab. (1995) 15:547-551. Novel approach for delivery.
37. RELTON J, MARTIN D, THOMPSON R, RÜSSEL D: Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp. Keurol. (1996) 138:206-213. May have future clinical application.
38. SHARIEFM.HENTGESR: Association between TNFa and disease progression in patients with multiple sclerosis. N. Engl.J. Mcd. (1991) 325:467-472.
39. LIU T, CLARK RK, MCDONNELL PC et al.: Tumor necrosis factor expression in ischémie neurons. Stroke (1994) 25:1481-1488.
40. WANG X, YUE T, BARONE F: Concomitant cortical expression of TNI'a inRNA following transient focal ischemia. Mol. Cbem. Netiropatbol. (1994) 23:103-114.
41. CHAO C, EHRLICH L, PETERSON P: IL-1 and TNFa synergistically mediate neurotoxicity. Brain Bebai: Immun. (1995) 374:647-650.
42. MEISTRELL M, COCKROFT KM, BOTCHKINA GI et al: TNF mediates brain damage hi stroke. Strote (1997) 28:255.
43. HALLENBECK JM: Cytokines, macrophages, and leukocytes in brain ischemia. In: Advances in Stroke Management: Proceeding Highlights. Sherman DG (Ed.) (1996) 5:5-10.
44. LAVINE S, HOFMAN F, ZLOKOVIC B: Circulating antibody against TNFa protects rat brain from reperfusion injury.J. Cereb. Blood Flow Metab. (1998) 18:52-58.
45. BRUCE A, BOLING W, KINDY M et ah Altered neuronal and microglial responses to excitotoxic and ischémie brain injury in mice lacking TNF receptors. Nat. Med. (1996) 2:788-794.
46. ZHAI QH, FUTRELL N, CHEN FJ: Calcium bound calmodulin is upregulated following TNFa inhibition with antisense oligonucleotide after middle cerebral artery occlusion (MCAO) in the rat. Stroke. (1997) 28:225.
47. AKIRA S, TAGA T, KISHIMOTO T: Interleukln-6 hi biology and medicine. Adv. Immunol. (1993) 54:1-78.
48. MATHIESEN T, ANDERSSON B, LOFTENUS A, VON HOLST H: Increased interleukin-6 levels incerebrospinal fluid following subarachnoid hemorrhage. J. Neurosurg. (1993) 78:562-567.
49. MERRILL JE, STROM SR, ELLISON GW, MYERS LW: In vitro study of mediators of inflammation in multiple sclerosis. J. Clin. Immunol. (1989) 9:84-96.
50. HIROHATA S, MIYAMOTO T: Elevated levels of Interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous systern involvement. Arthritis. Rheum. (1990) 33:644-649.
51. GIJBELS K, VANDAALME J, PROOST P, PUT W, CARTON H, BILUAU A: Interleukin-6 production in the central nervous system during experimental autoimmune encephalomyelitis. Eur.J. Immunol. (1990) 20:233-235.
52. WANG X, YUE T-L, YOUNG PR, BARONE FC, FEUERSTEIN GZ: Expression of interleukin-6, c-fos, and zif268 mRNA in rat ischémie cortex-J. Cereb. Blood Flow Atetab. (1995) 15:166-171. Initial report of IL-6 time course.
53. TAUPIN V, TOULMOND S, SERRANO A, BENAVIDES J, ZAVALA F: Increase in IL-6, JL-1, and TNF levels in rat brain following traumatic lesion. Influence of pre- and post-traumatic treatment with Ro5 4864, a peripheral type (p site) benzodiazepine liquid. J. Neuroimmunol. (1993) 42:177-185.
54. KUKIELKA GL, SMITH CW, MANNING AM, YOUKER KA, MICHAEL LH, ENTMAN ML: Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Stroke (1995) 92:1866-1875.
55. CLARK W, LAUTEN J, COULL B, CHERRY N, WOODWARD W: ICAM-1 and IL-6 changes in the hippocampus following transient forebrain ischemia in the rat. Soc. Keurosci. (1993) 19:1664.
56. CLARK W, RINKER L, LESSOV N, HAZEL K: Time course of IL-6 expression in experimental CNS ischemia. Neural. Res. (1999) 21:287-292.
57. TOULMOND S, VICE X, FACE D, BENAVIDES J: Local infusion of interleukin-6 attenuates the neurotoxic effects of NMDA on rat striatal cholincrgic neurons. Neiirosci. Lett. (1992) 144:49-52.
58. CAMPBELL IL, ABRAHAM CR, MASLIAH E et al.: Neurologie disease induced in transgenic mice by cerebral overexpression of Intcrlcukin-6. Proc. Natl. Acad. Set. USA (1993) 90:10061-10065.
59. ROTHWELL NJ, RELTON JK: Involvement of cytoklnes In acute neurodegeneration in the CNS. Neiirosci. Biobebav. Rev. (1992)17:217-227.
60. SELMAJ KW, FAROOQ M, NORTON WT, RAINE CS, BROSNAN CF: Proliferation of astrocytes in vitro in response to cytoklnes. J. Immunol. (1990)144:129-135.
61. CLARK W, RINKER L, LESSOV N et al.: Lack ofIL-6 expression is not protective against focal CNS ischemia. Stroke (2000) 31:1715-1720. Initial report of IL-6 modulation in CNS ischaemia.
62. BEAMER NB, COULL BM, CLARK WM, HAZEL JS, SILLSERGER JR: Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann. Neural. (1995) 37:800-804. Initial report of IL-lra levels post stroke.
63. CLARK WM, HAZEL JS, BEAMER N, WYNN M, COULL B: The initial acute phase response predicts long term stroke recovery. S;rote(1996) 27:186.
64. ELNEIHOUM AM, FALKE P, AXELSSON L, LUNDBERG E, LINDGARDE F, OHLSSON K: Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischémie cerebrovascular diseases. Stroke (1996) 27:1734-1738.
65. CLARK WM, COULL BM, BEAMER NB: Need for treatment of elevated plasma fibrinogen levels In cerebrovascular disease. Heart Dis. Stroke (\993) 2:503-506.
66. COULL BM, BEAMER N, CLARK WM: Elevated plasma interleukin-6 in acute stroke. Stroke (1993) 24:183.
67. YOUKER KA, SMITH CW, ANDERSON DC et al.: Neutrophll adherence to isolated adult cardiac myocytes: induction by cardiac lymph collected during ischemia and reperfusion. / Clin. Inivst. (1992) 89:602-609.
68. ZHANG R, CHOPP M, JIANG N et al.: Anti-intercellular adhesion molecule-1 antibody reduces ischémie cell damage after transient but no permanent middle cerebral artery occlusion in the wistar rat. 5/rofa?(1995) 26:1438-1443.
69. ENUMOMAB ACUTE STROKE TRIAL INVESTIGATORS: Enlimomab acute stroke trial; final results. Neurology (2001) (In press).
70. FROHMAN EM, FROHMAN TC, DUSTIN ML et al.: The induction of intracellular adhesion molecule 1 (ICAM-1) expression on human fetal astrocytes by interferon-y, tumor necrosis factor a, lymphotoxin, and interleukin-1: relevance to intracerebral antigen presentation. J. Keuroimmunol. (1989) 23:117-124.
71. POBER JS, GIMBRONE MA, LAPIERRE LA et al.: Overlapping patterns of activation of human endothelial cells by interlukin-1, tumor necrosis factor, and immune interferon. / Immunol. (1986) 137:1893-1896.
72. CHUNG IY, BENVENISTE EN: TNF-a production by astrokcytes: induction by lipopolysaccharlde, interferon-gamma and interlcukin-1. J. Immunol. (1990) 144:2999-3007.
73. LIEBERMAN AP, PITHA PM, SHIN HS, SHIN ML: Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopotysaccharide or a neurotropic virus. Proc. Natl. Acad. Sei. USA. (1989) 867:6348-6352.
74. CLARK WM, LAUTEN JD, BEAMER NB, COULL BM: Cytokine and Superoxide production in clinical stroke.J. Stroke Cerebmvasc. Dis. (1995) 5:166-171.
75. CLARK WM, LAUTEN JD, LESSOV N, WOODWARD W, COULL BM: Time course of ICAM-1 expression and leukocyte subset infiltration in rat forebrain ischemia. Mol. Cbem. Keuropathol. (1995) 26:213-230.
76. NAWASH1RO H, TASAKI K, RUETZLER ÇA, HALLENBECK JM. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J. Cereb. Blood FlowMetab. (1997) 17(5):483-490.
77. SPERA P, ELUSON J, FEURSTHN G, BARONE F: IL-10 reduces rat brain injury following focal stroke. Neurosci. Lett. (1998) 251:189-192.
78. KUMAR S,. MCDONELL P, GUM R, HAND A, LEE J, YOUNG P: Novel homologues of p38 MAP kinase. Blocbem. Blophys. Res. Comm. (1997) 235:533-538.
79. BARONE F, FEUERSTEIN G, WHITE R, IRVING E PARSONS A: Selective inhibition of p38 mitogen activated kinase reduces brain injury and neurological deficits in the rat. J. Cereb. Blood Flow Metab. (1999) 19:613.